Last reviewed · How we verify
MDMA assisted psychotherapy
At a glance
| Generic name | MDMA assisted psychotherapy |
|---|---|
| Also known as | MDMA-assisted CBCT |
| Sponsor | Remedy |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study) (PHASE2)
- MDMA-assisted Therapy for Fibromyalgia (EARLY_PHASE1)
- MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder (PHASE2, PHASE3)
- MDMA-Assisted Therapy for Pathological Narcissism (EARLY_PHASE1)
- Social Anxiety MDMA-Assisted Therapy Investigation (PHASE2)
- High-Intensity Inpatient MDMA-Assisted Psychotherapy for PTSD (PHASE2)
- MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD (PHASE2)
- Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MDMA assisted psychotherapy CI brief — competitive landscape report
- MDMA assisted psychotherapy updates RSS · CI watch RSS
- Remedy portfolio CI